Ivologist review

Ivologist’s starter sermorelin injection is advertised at $50 per week over four weeks, with consultation, medication, supplies and support described as included. The default NAD⁺ injection option shows $115 per month over two months. Its nasal NAD⁺ and extended sermorelin selections lack a verified current public price, and the full first debit is unstated. A consultation deposit is credited toward the program cost; mobile IV service is local to two Texas cities.

Ivologist is operated by Ivologist Weight Loss Center, LLC, a Texas company whose terms give its principal place of business as 26331 Tawny Way, Boerne, Texas. Its categories run across weight and metabolism, hormone therapy, peptides, wellness and longevity, and supplements, and it reports serving more than 40,000 patients. Its peptide menu currently lists BPC-157, sermorelin and NAD⁺ as available, with GHK-Cu, TB-500, tesamorelin, MOTS-c, epithalon, glutathione and AOD-9604 marked "coming soon". Sermorelin is offered as a 9 mg injectable on a four-week protocol or an 18 mg injectable on an eight-week one; NAD⁺ comes as an injectable or a nasal spray. Its site banner states weight and metabolic care described both as all 50 states and most states, hormone and wellness care in "select" states, and mobile IV therapy in San Antonio and El Paso, Texas.

A hybrid, and an honest one to describe as such. Telehealth handles weight, hormones and wellness; a mobile IV service handles in-person administration, only in two Texas cities. For an injectable product, a clinician physically present is a different level of oversight from a vial in the post, but that option is not available to most readers, and sermorelin or NAD⁺ bought through telehealth is self-administered. The sermorelin page sets out a five-step path — intake, clinician review, lab work ordered after the evaluation to assess hormone levels, delivery from a partner pharmacy, and follow-up with dose adjustments. Labs appearing in the default path for a growth-hormone-axis compound is a real point in its favor, though the page does not say whether they cost extra. Coverage is the catch. The wellness line, which includes sermorelin and NAD⁺, is offered only in select states, and those states are not listed, so eligibility is confirmed at intake. The FAQ states that any deposit is applied toward the total program cost. No compounding pharmacy is named; the peptides page says only that they are compounded by licensed 503A or 503B pharmacies.

The selected 9 mg starter sermorelin injection is $50 per week for a four-week protocol. An extended 18 mg option appears, but its selected price and first debit were not confirmed. Default injectable NAD⁺ is $115 per month on a two-month program; the separate nasal selection did not yield a verifiable current price on the public product page. These weekly and monthly labels do not establish the upfront program charge. The homepage says a deposit is applied to the total program cost. Terms say cancellation takes effect after the paid term and sales are final except when a provider declines treatment. Ask for the selected route, lab charges, first debit and renewal terms before paying.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Ivologist says it is LegitScript-certified, which concerns legal and regulatory operation rather than whether a product works, and it names no compounding pharmacy — compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are. On the evidence, the site's own description of sermorelin is accurate as far as it goes: it does stimulate growth-hormone release from the pituitary, and that is a real, well-described mechanism. What the description omits is that mechanism is where the evidence stops. No controlled human trial shows compounded sermorelin delivers the body-composition, recovery or anti-aging outcomes the category is sold on, and the long-term human data stays thin. Injected NAD⁺ is weaker still — no controlled human outcome trials at all, with the single human intravenous study a pharmacokinetic pilot finding that infused NAD⁺ clears from plasma quickly. The NAD⁺ forms with human trial data are the oral precursors NR and NMN, which reliably raise blood NAD⁺ — a raised biomarker rather than a demonstrated clinical benefit. Individual results vary.